Gilead backs $60M Hookipa round to fund immunotherapy R&D – FierceBiotech
FierceBiotech |
Gilead backs $60M Hookipa round to fund immunotherapy R&D
FierceBiotech Gilead backs $60M Hookipa round to fund immunotherapy R&D. by Nick Paul Taylor |. Dec 11, 2017 8:11am. gilead4. Hookipa is developing a pipeline derived from two arenavirus-based vector platforms: Vaxwave and TheraT. Share Facebook Twitter LinkedIn … |
